Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $138.90M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 3.91M
Average 8.14M
HUMA Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Humacyte, Inc.NASDAQ: HUMA
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$362K, compared with $653K a year earlier. Trailing-twelve-month accounts payables was -$42K.
Context
- Accounts payables amounted to 47.7% of revenue in FY2025.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near -$362K or moves back toward the trailing-twelve-month quarterly average of -$10.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 973K USD
- Year-over-year change
- +149.6%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 973K | +149.6% |
| FY2024 | 2024-12-31 | (1.96M) | -140.8% |
| FY2023 | 2023-12-31 | 4.81M | +1045.2% |
| FY2022 | 2022-12-31 | (509K) | -158.4% |
| FY2021 | 2021-12-31 | (197K) | — |
Accounts Payables vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 accounts payables of $42K is the 10th largest of the 11 companies compared; the peer median is $143.25K.
- Its year-over-year change of -102.6% is the 10th highest of 11, against a peer median of +100.9%.
- Accounts payables amounts to 2.1% of revenue for HUMA, versus a peer median of 4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $11.66M | +88.8% | +10.3% | 5.4% | |
| LTM Mar 2026 | $2.19M | -26.1% | -1.7% | 4.8% | |
| LTM Mar 2026 | $2.06M | +115.0% | — | — | |
| LTM Mar 2026 | $824K | -164.2% | — | — | |
| LTM Mar 2026 | $793K | -49.2% | -33.2% | 2.8% | |
| LTM Mar 2026 | $752K | +384.8% | — | 13.1% | |
| LTM Mar 2026 | $262K | +132.6% | -50.3% | — | |
| LTM Mar 2026 | $197.49K | +121.5% | — | — | |
| LTM Mar 2026 | $89K | +101.8% | -20.1% | 0.2% | |
| LTM Mar 2026 | $42K | -102.6% | — | 2.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | +100.0% | — | — |
| Peer median (excluding HUMA) | $143.25K | +100.9% | -20.1% | 4.8% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 5.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.15M | 6.18M | 6.83M | 6.14M | 9.75M |
| Change in Working Capital | (557K) | 1.03M | 6.57M | 311K | (23.4M) |
| Accounts Receivables | (63K) | 145K | 31K | 0 | (261K) |
| Inventory | 0 | 0 | 0 | 0 | (21.83M) |
| Accounts Payables | (197K) | (509K) | 4.81M | (1.96M) | 973K |
| Other Working Capital | (297K) | 1.39M | 1.73M | 2.27M | (2.28M) |
| Other Non-Cash Items | (72.54M) | (74.59M) | 16.35M | 36.94M | (55.9M) |
| Operating Cash Flow | (81.19M) | (71.13M) | (73.31M) | (98.12M) | (105.04M) |
| Capital Expenditures | (220K) | (1.05M) | (2.28M) | (1.57M) | (884K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (8M) | (10.11M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 16M | 2.11M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (8.22M) | 4.85M | (173K) | (1.57M) | (884K) |
| Debt Repayment | 27.93M | (1.98M) | 5.7M | (2.58M) | 36.39M |
| Common Stock Issued | 598K | 535K | 566K | 45.93M | 113.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 239.05M | 535K | (1.76M) | 27.71M | (88.34M) |
| Financing Cash Flow | 266.98M | (1.45M) | 4.51M | 114.18M | 61.49M |
| Effect of Forex Changes | 0 | 0 | (209K) | 0 | 0 |
| Net Change in Cash | 177.57M | (67.73M) | (69.18M) | 14.49M | (44.44M) |
| Free Cash Flow | (81.41M) | (72.18M) | (75.59M) | (99.69M) | (105.93M) |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.